A Multicenter, Double-masked, Placebo-controlled, Efficacy and Safety Study of an Insulin-like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), in Patients With Active Thyroid Eye Disease

Trial Profile

A Multicenter, Double-masked, Placebo-controlled, Efficacy and Safety Study of an Insulin-like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), in Patients With Active Thyroid Eye Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2017

At a glance

  • Drugs Teprotumumab (Primary)
  • Indications Graves ophthalmopathy
  • Focus Therapeutic Use
  • Sponsors Horizon Pharma; River Vision Development Corp
  • Most Recent Events

    • 08 May 2017 According to Horizon Pharma Media release, River Vision Development Corp is acquired by Horizon Pharma on May 2017
    • 04 May 2017 Primary endpoint (Clinical Activity Score) has been met.
    • 04 May 2017 Results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top